Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Parkinson’s Disease Treatment Market
5.1. COVID-19 Landscape: Parkinson’s Disease Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Parkinson’s Disease Treatment Market, By Drug Class
8.1. Parkinson’s Disease Treatment Market, by Drug Class, 2022-2030
8.1.1. Carbidopa-levodopa
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Dopamine Agonists
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. MAO-B Inhibitors
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. COMT inhibitors
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Anticholinergics
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Parkinson’s Disease Treatment Market, By Distribution Channel
9.1. Parkinson’s Disease Treatment Market, by Distribution Channel, 2022-2030
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Online Pharmacy
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Parkinson’s Disease Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 11. Company Profiles
11.1. Cerevel Therapeutics
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Novartis AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Teva Pharmaceutical Industries Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Merck & Co., Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. GlaxoSmithKline plc. (GSK)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. AbbVie, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. H. Lundbeck A/S
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Amneal Pharmaceuticals LLC
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Supernus Pharmaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms